Managers / Q1 2021 · view latest →
RHO CAPITAL PARTNERS INC
CIK 0001020455 · 152 WEST 57TH STREET, 23RD FLOOR, NEW YORK, NY, 10019 · 212-751-6677
Summary
Rho Capital Partners Inc reported $1.0B in U.S.-listed holdings across 7 positions for Q1 2021.
The portfolio is heavily concentrated: Chargepoint alone accounts for 64.3% of reported value.
Compared with Q4 2020, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 67.1% · $698M
- Common Stock · 32.9% · $342M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CHARGEPOINT HOLDINGS INC | NEW | +25.06M | 25.06M | +$669M | $669M |
| ONTFON24 INC | NEW | +3.64M | 3.64M | +$176M | $176M |
| CARA THERAPEUTICS INC | TRIMMED | −250.0K | 2.55M | +$13M | $55M |
| MERSANA THERAPEUTICS INC | HELD | +0 | 796.5K | −$8M | $13M |
| NGM BIOPHARMACEUTICALS INC | HELD | +0 | 3.77M | −$5M | $109M |
| LIVEXLIVE MEDIA INC | HELD | +0 | 3.72M | +$4M | $16M |
| SENSEONICS HLDGS INC | HELD | +0 | 159.6K | +$282,000 | $421,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CHARGEPOINT HOLDINGS INC | COM CL A | 64.34% | $669M | 25.06M |
| 2 | ONTFON24 INChistory → | COM | 16.97% | $176M | 3.64M |
| 3 | NGM BIOPHARMACEUTICALS INC | COM | 10.53% | $109M | 3.77M |
| 4 | CARA THERAPEUTICS INC | COM | 5.32% | $55M | 2.55M |
| 5 | LIVEXLIVE MEDIA INC | COM NEW | 1.55% | $16M | 3.72M |
| 6 | MERSANA THERAPEUTICS INC | COM | 1.24% | $13M | 796.5K |
| 7 | SENSEONICS HLDGS INC | COM | 0.04% | $421,000 | 159.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2023 | $20M | 3 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $39M | 3 | Aug 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $41M | 3 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $63M | 4 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $59M | 4 | Aug 1, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $145M | 5 | May 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $154M | 5 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $179M | 7 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.1B | 7 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.0B | 7 | May 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $190M | 5 | Feb 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $120M | 5 | Nov 23, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $154M | 5 | Aug 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $99M | 5 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $132M | 5 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $119M | 5 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $144M | 5 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $94M | 5 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.